The current and projected economic burden of Parkinson's disease in the United States. - Wikidata - awgldk - TriplyDB

The current and projected economic burden of Parkinson's disease in the United States.

The current and projected economic burden of Parkinson's disease in the United States.

http://www.wikidata.org/entity/Q44988421

about

Sex and Gender Differences in Central Nervous System-Related Disorders Deep Brain Stimulation: A Paradigm Shifting Approach to Treat Parkinson's Disease Predictive Big Data Analytics: A Study of Parkinson's Disease Using Large, Complex, Heterogeneous, Incongruent, Multi-Source and Incomplete Observations.Deep brain stimulation for disorders of memory and cognition Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic Time to change the blind men and the elephant approach to Parkinson disease?The role of leptin in central nervous system diseases Immunomodulators as Therapeutic Agents in Mitigating the Progression of Parkinson's Disease Constipation preceding Parkinson's disease: a systematic review and meta-analysis.Sex Differences in Clinical Features of Early, Treated Parkinson's Disease.Parkinson disease male-to-female ratios increase with age: French nationwide study and meta-analysis.Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial.Deep brain stimulation for movement disorders Healthcare Data Analytics for Parkinson's Disease Patients: A Study of Hospital Cost and Utilization in the United States.Effects of a formal exercise program on Parkinson's disease: a pilot study using a delayed start design.A randomized trial of individual versus group-format exercise and self-management in individuals with Parkinson's disease and comorbid depression.Wound research funding from alternative sources of federal funds in 2012.High expression levels of the D686N Parkinson's disease mutation in VPS35 induces α-synuclein-dependent toxicity in yeast Unbiased approaches to biomarker discovery in neurodegenerative diseases Correlation between decreased CSF α-synuclein and Aβ₁₋₄₂ in Parkinson disease.An overview on the correlation of neurological disorders with cardiovascular disease.Digital Health Revolution: Is it Time for Affordable Remote Monitoring for Parkinson's Disease?The role of astrocyte mitochondria in differential regional susceptibility to environmental neurotoxicants: tools for understanding neurodegeneration Person-Centered Care in the Home Setting for Parkinson's Disease: Operation House Call Quality of Care Pilot Study.An Aminopropyl Carbazole Derivative Induces Neurogenesis by Increasing Final Cell Division in Neural Stem Cells.Economic Evaluation of a Tai Ji Quan Intervention to Reduce Falls in People With Parkinson Disease, Oregon, 2008-2011.Dynamic High-Cadence Cycling Improves Motor Symptoms in Parkinson's Disease.A randomized, double-blind phase I/IIa study of intranasal glutathione in Parkinson's disease.The Role of DNA Methylation and Histone Modifications in Neurodegenerative Diseases: A Systematic Review Deep Brain Stimulation: Expanding Applications.Association Between Tuberculosis and Parkinson Disease: A Nationwide, Population-Based Cohort Study.Quality improvement in neurology: Parkinson disease update quality measurement set: Executive summary.Serum 25-hydroxyvitamin D concentrations in Mid-adulthood and Parkinson's disease risk.National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease: Interest and Barriers.Gender differences in the adverse events' profile registered in seven observational studies of a wide gender-medicine (MetaGeM) project: the MetaGeM safety analysis.Upregulation of Glutaredoxin-1 Activates Microglia and Promotes Neurodegeneration: Implications for Parkinson's Disease NADPH oxidase in brain injury and neurodegenerative disorders Sexual dimorphism in Parkinson's disease: differences in clinical manifestations, quality of life and psychosocial functioning between males and females.Trends in antiparkinsonian medication use in new zealand: 1995-2011.First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers

P2860

Q26744569-6249860E-5A25-48B8-8E0F-13B6E763A375 Q26747575-BF3C651A-9BE1-4289-BAB4-D1ADD09856D6 Q26779516-0E94EB94-07D3-458D-A85A-C522AEEDC651 Q26859169-726D42A7-1E61-41AF-B7D5-25FE316FFAD9 Q27007413-EDC911B4-596B-43E4-B914-681ECC0A3073 Q27693350-BC901066-DABC-4E8E-BAD2-2AE0EA864759 Q28069664-4214517B-F991-4226-92F3-704B21E91319 Q28079187-E44F7E2C-632D-4E96-9FBA-DEE1DDB9E12E Q30252096-FF1A7076-B9A8-407F-A8DA-F26EDC933C69 Q30375563-CBF64F61-C24B-455C-A25B-9AEE824B69B4 Q30381816-5F213811-C604-47D1-9EC5-49166E73FD68 Q30407589-017F49C3-4A2A-48FF-B175-4C5F00ACFD45 Q30585845-17DB23AE-EC10-420D-866A-81078CD1B136 Q31172400-3BE5B663-0BD7-45BE-84BB-3F0522BCCFCF Q33648828-BCCEB909-219A-4660-A673-6FCCA65763D9 Q33739875-03BEBF1C-3C74-4266-81C1-FC5C99D8C038 Q33763808-ABBF1DBC-1499-4437-AE80-59B16732EB83 Q33827945-E9FBB0FF-59A1-4D08-82FA-A1546C2EC807 Q34625918-6B45D995-80E0-4EAD-A557-85561683944D Q34714560-14831668-9B48-4AEA-AA35-43D137BE105B Q34800195-66C7DF71-C4DD-4455-8F38-C94937F9FE52 Q35124368-882C9664-9E6D-4C1A-8BC8-7E9313B2B15A Q35145894-094484BC-D279-43B2-8A30-3C3ABD2A4FB3 Q35675060-AF630B02-78B0-44C5-B6D4-E8E5537AA8BD Q35811453-12D789C9-C140-46D5-AFBA-F30EF1A686A5 Q35911113-A45F3444-9372-4131-A798-C56939303F71 Q36018225-28961046-8A41-4103-980F-76341C7B6D09 Q36172557-343003C3-4A70-4A64-AFAD-56466BB9A77F Q36223734-0EFEA143-2EB3-4626-9B0E-5450EDC484AD Q36391409-3FC9E808-8DC7-45A4-8A59-F3A7C081306A Q36653647-50031C11-4224-440E-8C41-96F40E83D555 Q37008911-EA3B1212-4928-4F68-BE56-AF4B0A27E42C Q37062741-0615D358-27B2-4CD5-B82E-3B0D3456D0F6 Q37081102-85393C4D-2B1C-4B42-BD3A-3116ADBE909C Q37265697-073CA058-983F-4343-884E-017653AEA6D6 Q37523363-4B224AF0-8D8B-47C6-8705-428E0762982B Q37589114-190E8CF1-F2D4-4650-A9E2-489E7482B1AC Q37629567-EF2782FF-8043-4EB2-8C63-404E422C69E7 Q37651160-B1FA767E-8C93-438F-A260-B090282C4B44 Q37664213-655CF170-2A99-4DE9-AFCB-7601A7F7C556

P2860

The current and projected economic burden of Parkinson's disease in the United States.

http://www.wikidata.org/entity/Q44988421

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

The current and projected economic burden of Parkinson's disease in the United States.

@en

The current and projected economic burden of Parkinson's disease in the United States.

@nl

type

label

The current and projected economic burden of Parkinson's disease in the United States.

@en

The current and projected economic burden of Parkinson's disease in the United States.

@nl

prefLabel

The current and projected economic burden of Parkinson's disease in the United States.

@en

The current and projected economic burden of Parkinson's disease in the United States.

@nl

P1433

Q44988421-152E4E46-A5BA-4CD0-A96E-BFAEE81908F0

P1476

Q44988421-2B6F2C3E-6E6A-488F-B584-0563A6181135

P2093

Q44988421-4CCA52FD-FD36-4B11-94F1-FB87931E9426

Q44988421-7DFA380F-36CD-4C32-A68D-2DB394F32C23

Q44988421-D1119B2A-1878-4B64-9D73-F5CA1D3129B1

Q44988421-F87FAE39-6F39-4E60-BA6B-E74D2EEA973F

P2860

Q44988421-05A0586B-4165-4CA4-8D42-D450AB48C156

Q44988421-172D0DB4-936E-4C3A-B9AA-A08B413B6DA5

Q44988421-235DB34A-CB99-43D4-A500-DC4F8D5A08B0

Q44988421-48461286-18B8-4D27-9F42-0DC6FDF99F96

Q44988421-57C6CA0C-9A19-4085-A19D-33C0A14619F7

Q44988421-8CC8D6DB-78A5-4F2B-86FD-D6CF800FC7FF

Q44988421-913A2AB8-D489-4E74-8BD9-55F7BDCB9C24

Q44988421-973E65D7-3EF6-40EF-B755-944A70AEA088

Q44988421-98A1F353-1669-4AA3-BE92-ABDCA610F913

Q44988421-A9F80FF3-2EAC-4DA5-B666-ADB8B45449AE

P304

Q44988421-EFE0963E-9C7F-48B2-B538-A75A2107F16E

P31

Q44988421-A0AE424A-1E06-4573-90F5-44E6029F93EF

P356

Q44988421-80051228-40F0-4CCC-B5D6-F6B6EFC7CEE3

P407

Q44988421-FB9133AD-DF3E-421C-BF7C-DEE755253C9C

P433

Q44988421-BD5A2BE9-6AD8-4D70-94C5-59294901941A

P478

Q44988421-FDE240DC-B288-4694-BC75-8EE8F62DC408

P50

Q44988421-16E1F677-BD46-450D-A53B-A310808B82AF

P577

Q44988421-EDC95E29-361B-4DBA-A438-EAD22A4DD51F

P698

Q44988421-D7FBA7F5-9EF6-40C0-8596-4CD47123258B

P921

Q44988421-446F0220-1A2E-47A5-A363-A5AEF359C306

P356

P1433

Movement Disorders

P1476

The current and projected economic burden of Parkinson's disease in the United States.

@en

P2093

Anjali Jain

http://www.w3.org/2001/XMLSchema#string

Michael V Storm

http://www.w3.org/2001/XMLSchema#string

Ritashree Chakrabarti

http://www.w3.org/2001/XMLSchema#string

Stacey L Kowal

http://www.w3.org/2001/XMLSchema#string

P2860

How common are the "common" neurologic disorders?

Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990.

Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity.

Neuroprotection trials in Parkinson's disease: systematic review.

The relative health related quality of life of veterans with Parkinson's disease.

A review of the health-related quality of life and economic impact of Parkinson's disease.

Predictors of survival in patients with Parkinson disease.

Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030.

Burden of illness in Parkinson's disease.

Economic burden associated with Parkinson's disease on elderly Medicare beneficiaries.

P304

311-318

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MDS.25292

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Timothy M. Dall

P577

2013-02-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23436720

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease